13 RESULTS
COMMENT This is a very nice new paper from Yassine et al. revealing significant associations between low serum docosahexaenoic acid (DHA) concentrations and (i) brain amyloid load (PiB PET), (ii) smaller brain volume (MRI), and (iii) impaired nonverbal memory in
COMMENT Although correlative studies strongly support associations between hyperphosphorylated tau, tangles, and AD symptoms (Tremblay et al., 2007; Bennett et al., 2004; Ghoshal et al., 2002), investigations in animals have not yet confirmed how tau acquires its
COMMENT The study is interesting, as it further confirms the importance of diets on markers related to AD neuropathology. It is focused on glial activation, which makes sense, as it replicates previous work showing high energy intake from fat increases GFAP (Buck
COMMENT We clearly need to wait until the release of the complete data before drawing conclusions. However, what clearly strikes me here is the difference between the interpretations made from clinical versus basic science data. On the one hand, randomized clinic
COMMENT The search for brain drug delivery vectors has not yielded much success. Therefore, the discovery a few years ago that decreasing the affinity of antibodies to the transferrin receptor (TfR) actually increased their access to the brain was a groundbreakin
COMMENT The debate continues about which key modifications turn tau into a neuron killer. This study by Min et al. provides support for an original hypothesis suggesting that acetylation of tau is a key event in its pathogenicity. Using two antibodies they have d
COMMENT A critical question indeed. We should answer that. The evaluation of cognitive function may lack sensitivity, specificity and may be insufficiently quantitative. Measurement of a critical biomarker may be as helpful? At the moment, biomarkers are just sur
COMMENT I think it would have been a major advantage to get Ketasyn/AC1202 FDA-approved as a drug. Ketasyn/AC1202 could have then been used by health professionals and prescribed to the right persons. There is a strong rationale in using medium chain triglyceride
COMMENT This paper from He et al. adds to the mounting evidence that omega-3 polyunsaturated fatty acids exert a neuroprotective action in the brain. In the various experimental paradigms presented, Fat-1 mice were protected from the deleterious effects of a diet
COMMENT The prospective study of Ernst Schaefer et al. suggests an interesting link between blood docosahexaenoic acid (DHA) and the onset of all-cause dementia. This is the follow-up of preliminary findings published in a research letter in 1999 (Kyle et al., 19
COMMENT To determine the efficacy of any drug, randomized clinical trials (RCTs) remain the gold standard. The same is true to find out if omega-3 polyunsaturated fatty acids (n3PUFAs) are beneficial in Alzheimer disease (AD), and Freund-Levi et al. published the
COMMENT The recent paper of Frédéric Darios and Bazbek Davletov adds up to recent studies trying to decipher the molecular mechanism of action of neuroactive lipids such as omega-3 (n3) polyunsaturated fatty acids (PUFAs). Many cellular effectors of n3PUFAs have
COMMENT This report from Akbar and Kim adds to their earlier work in this area by providing compelling evidence for an impact of DHA on enhancing the rate of PI3K>Akt signaling in neurons and brain by increasing phosphatidylserine (PS) and translocation-depend
